Wed, Jul 23, 2014, 2:40 AM EDT - U.S. Markets open in 6 hrs 50 mins


% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • carcorpgm carcorpgm Jan 3, 2013 6:56 PM Flag

    Maybe Iplex isn't dead

    Biogen Idec's (Nasdaq: BIIB) potential treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, has failed in a late-stage clinical trial, disappointing the company, patients and doctors. In a best-case scenario, that Phase 3 trial would have formed the basis of an application for U.S. Food and Drug Administration (FDA) approval.

    Weston, Mass.-based Biogen’s stock slid more than 3 percent Thursday morning, to $144.79, from a previous close of $150, after the company announced the news.

    The failure of the 900-patient Empower trial was so complete that the company will abandon development of the drug candidate, called dexpramipexole, or Dex.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
17.70-0.04(-0.23%)Jul 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.